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Background: Studies have shown that nonspecific interstitial pneumonitis (NSIP), even when initially diagnosed as
an idiopathic form of the disease, might be associated with an autoimmune background that later reveals itself as
an organ-specific or a systemic autoimmune disease.
Methods: NSIP patients were divided into three groups. The NSIP patients who met the criteria for having a systemic
autoimmune disease (SAD) were defined as the systemic autoimmune disease-associated NSIP (SAD-NSIP) group. The
NSIP patients who did not meet the criteria for a systemic autoimmune disease were defined as an antibody-positive
group (i-NSIP-Ab + group) if their sera were positive for autoantibodies. The NSIP patients with negative serologic tests
for auto-antibodies were defined as the antibody-negative group (i-NSIP-Ab- group). The clinical characteristics
were analyzed and compared among the three groups.
Results: Ninety-seven NSIP patients were included. The mean age of the study population was 48 ± 11 years. The
mean follow-up time was 54 ± 34 months. At the time of the surgical lung biopsies, 23/97 (23.7%) of the patients
were classified as SAD-NSIP; 30/97 (30.9%) were in the i-NSIP-Ab + group; and 44/97 (45.4%) were in the i-NSIP-Ab- group.
At the end of the follow-up period, three cases were diagnosed with polymyositis (one case from the
i-NSIP-Ab + group, two cases from the i-NSIP-Ab- group), one with scleroderma (from the i-NSIP-Ab + group,
scl-70 positive and skin biopsy) and another one with microscopic polyarteritis (from the i-NSIP-AB-group, p-ANCA and
MPO positive, renal biopsy). Three cases in the i-NSIP-Ab- group were later found to be positive for autoantibodies. Due
to these changes in classification, at the end of the follow-up period, the SAD-NSIP group consisted of 28/97 patients
(28.9%), the i-NSIP-Ab + group of 31/97 (32.0%) and the i-NSIP-Ab- group of 38/97(39.1%). There were no significant
differences in clinical manifestations, radiographic findings or pulmonary function tests among the three groups
at the time of surgical lung biopsy or after reclassification after the follow-up period. SAD was an independent
risk factor for the survival of the patients with NSIP after follow-up.
Conclusion: Follow-up is recommended because idiopathic NSIP may be the first manifestation of a systemic
autoimmune disease.
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The histopathologic pattern of nonspecific interstitial pneu-
monitis (NSIP) has been found in a wide variety of clinical
contexts, including chronic hypersensitivity pneumonitis,
drug-related interstitial pneumonia, and connective tissue
disease (CTD) [1-5]. NSIP has been identified as one of the
most common pathologic patterns in patients with CTD* Correspondence: ShiJH@pumch.cn
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unless otherwise stated.[6-11]. Recent studies have shown that NSIP, even when
initially diagnosed as an idiopathic form of NSIP, might be
associated with an autoimmune background that later re-
veals itself as an organ-specific or a systemic autoimmune
disease [12-14]. In a cohort study of 27 idiopathic NSIP
patients, more than 50% of the cases developed an auto-
immune disease after a mean follow-up of 22 months [13].
Furthermore, an Asian study revealed that CTD developed
in 10% of idiopathic NSIP patients during the follow-up
period [14]. It has been suggested that MultidisciplinaryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tablish the diagnosis of idiopathic NSIP [15,16].
Compared with idiopathic interstitial lung disease (ILD),
patients with CTD-associated ILD (CTD-ILD) had a better
prognosis [17-21]. For patients with rheumatoid arthritis-
associated usual interstitial pneumonia (UIP), the survival
time was longer than that for patients with UIP without
rheumatoid arthritis [18]. According to these studies, it
might be deduced that CTD-NSIP had a better outcome
than idiopathic NSIP (i-NSIP). However, the current litera-
ture is controversial. Additional studies showed that CTD
did not affect the survival of patients with pathologically
confirmed NSIP [22,23]. Interestingly, the classification of
undifferentiated CTD-NSIP conferred a minor prognostic
advantage [23].
Given that CTD-NSIP is similar to i-NSIP on clinical and
radiologic features [24-26], and if there are no differences
in the disease outcomes for the two classifications, the
question arises as to whether there is a value to differ-
entiating between CTD-NSIP and i-NSIP. To answer this
question, we reviewed the clinical, radiologic and physio-
logic findings in NSIP patients with systemic autoimmune
disease and i-NSIP at the Peking Union Medical College
Hospital. We wanted to evaluate whether there was a dif-
ference in prognosis for i-NSIP patients compared with
those with systemic autoimmune disease in this Chinese
cohort.
Methods
Study subjects and diagnostic criteria
Between December 2002 and December 2011, 354 patients
underwent surgical lung biopsies at the Peking Union
Medical College Hospital, the biggest referral center in
China. The ending date for the follow-up period was
December 2012. The 354 cases in this study were clinical
suspicion for diffuse infiltrates. NSIP was diagnosed in 101
cases; 4 cases of drug-induced NSIP were excluded. The
remaining 97 cases were enrolled in this study. Their clin-
ical features, radiological images and pathological findings
were reviewed and analyzed. NSIP was diagnosed accord-
ing to the American Thoracic Society (ATS)/European
Respiratory Society consensus classification criteria [1,15].
Informed consent for using the medical records was ob-
tained from every patient and/or their guardian when
the patient was admitted to the hospital. This study was
approved by Peking Union Medical College Hospital
Institutional Review Board (reference number for ethics
approval: 2013-9-322).
Patients with a history of drug toxicity, airborne antigen
or environmental exposures were excluded. Individual
forms of systemic autoimmune disease including CTD,
microscopic polyangiitis and Crohn's disease were diag-
nosed according to the criteria of the corresponding soci-
eties. The following were considered autoantibody positive(Ab+) in our study: an antinuclear antibody (ANA) titer
greater than 1:320, a positive of anti-Sjogren's syndrome
antigen A (SSA) or anti-Sjogren's syndrome antigen B (SSB),
anti-Scl-70, anti-Sm, anti-Jo-1, anti-ribonucleoprotein
antibody (anti-RNP), anti-keratin antibody (AKA), anti-
perinuclear factor (APF), or anti-cyclic citrullinated peptide
antibodies (anti-CCP) [27-32]. NSIP patients who meet the
criteria for a systemic autoimmune disease (SAD) were
defined as the SAD-NSIP group [30,33-35]; NSIP patients
who had at least one positive serologic antibody test were
defined as the antibody positive group (i-NSIP-Ab + group);
and NSIP patients with negative serologic antibodies tests
were defined as the antibody negative group (i-NSIP-Ab-
group).
Clinical characteristics
The patients in this study had the following clinical charac-
teristics documented at the time of their first visit: age, sex,
symptoms at the time of the surgical lung biopsy (cough,
dyspnea, or wheeze), symptoms or signs of systemic auto-
immune disease, smoking status, physical exam findings,
arterial blood gas analysis (ABG), and serologic auto-
antibody tests.
Pulmonary function tests
Spirometry, total lung capacity (TLC) by plethysmogra-
phy, forced vital capacity (FVC) and diffusing capacity of
the lung for carbon monoxide (DLCO) were measured
according to the ATS recommendations [36-38], and the
results were expressed as percentage of the normal pre-
dicted values.
Analysis of subsets of lymphocytes from bronchoalveolar
lavage fluid (BALF)
The patients were examined by bronchoscopy with an
electric video bronchoscope wedged into the segmental
bronchus of the right middle lobe. One hundred millili-
ters of sterile saline was injected according to the guide-
lines for the measurement of the cellular components
and standardization of BAL [39,40]. To evaluate the cell
subsets, the lymphocytes were stained with anti-CD3,
anti-CD4 and anti-CD8 monoclonal antibodies coupled
to fluorescein isothiocyanate, and the cellular fluorescence
was measured with a FACS Calibur flow cytometer.
High-resolution CT scanning
High-resolution computed tomography (HRCT) chest
scans were performed on all patients at the time of the
initial evaluation. The films were reviewed in a blinded
fashion by chest radiologists experienced in interpret-
ation of diffuse lung diseases. The specific findings of the
HRCT were documented for the index scan (the first scan
that documented the presence of ILD). The extent of
emphysema, ground-glass opacity (GGO), reticulation,
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a scale of 5% for all lobes. HC was defined as clustered cys-
tic airspaces, 3 to 10 mm in diameter, in the subpleural
areas of the lungs with well-defined shared walls and
layering.
Treatment and follow-up
After being diagnosed with NSIP, all patients received a
course of oral prednisolone, starting at 0.5 mg/kg/d for
one month, tapered every 3 weeks to 5-7.5 mg/d and then
maintained in 5-7.5 mg/d. The total length of treatment
was 12-18 months.
The patients underwent follow-up assessments at the
Interstitial Lung Disease Clinic of Peking Union Medical
College Hospital 3, 6 and 12 month after surgical lung bi-
opsy, and then once a year. The patients in the SAD-NSIP
group were treated combined with cytotoxic drugs.
Statistical analysis
All values are expressed as the mean ± SD. Student’s t-test
was used for analysis of normally distributed data. The
Wilcoxon test and Kruskal-Wallis test were used to com-
pare two or more sets of non-normally distributed data, re-
spectively. Fisher's exact test was used to determine group
differences. Cox multivariate regression analysis was used
to evaluate the survival risk factors. The overall survival





After follow up 28(28.9)
Age (years), Mean ± SD
Initial presentation 49.4 ± 10.6
After follow up 50.4 ± 9.9
Male
Initial presentation 6/23(26.1)
After follow up 8/28(28.6)
Duration (months), Mean ± SD
Initial presentation 16.7 ± 27.6
After follow up 14.9 ± 25.3
Follow-up time (months), Mean ± SD
Initial presentation 48.4 ± 28.2
After follow up 51.9 ± 29.8
Smoking,
Initial presentation 2/23(8.7)
After follow up 2/28(7.1)
The demographic characteristics are shown in above Table. There were no differenc
surgical lung biopsy or after re-classification at the time of follow-up.The correlation coefficients were calculated using Spear-
man’s rank method. The probability values were obtained
from 2-sided tests, with a statistical significance of p <
0.05. SPSS 15.0 (SPSS for Windows, version 15.0 [SPSS
Inc., Chicago, Illinois, USA]) was used for the statistical
analyses.
Results and discussion
Ninety-seven NSIP patients were included. The mean age
of the study population was 48 ± 11 years (median 48, range
16 to 69), and 73% were women. The mean follow-up time
was 54 ± 34 months (median 45, range 2 to 120).
We divided the NSIP patients into three groups accord-
ing the above criteria at the time of surgical lung biopsy.
The SAD-NSIP group included 23/97(23.7%) of the pa-
tients; the i-NSIP-Ab + group included 30/97 (30.9%);
and the i-NSIP-Ab- group included 44/97(45.4%). The
underlying types of systemic autoimmune disease were
rheumatoid arthritis (n = 3), scleroderma (n =3), Sjogren’s
syndrome (n =4), polymyositis (n = 9), SLE (n = 1), MPA
(n = 2) and ulcerative colitis (n = 1).
At the end of December 2012, typical clinic manifesta-
tions of CTD developed in five cases from i-NSIP-Ab +
group and i-NSIP-Ab- group. Respiratory symptoms
preceded other systemic manifestations by a median of
48 months (range 1-108). Additionally, 4 cases in the
i-NSIP Ab- group were later found to have positivei-NSIP-Ab + group i-NSIP-Ab-group P
N (%) N (%)
30(30.9) 44(45.4) 0.050
31(32.0) 38(39.1) 0.306
45.7 ± 10.0 49.5 ± 12.5 0.307
46.3 ± 10.6 48.5 ± 12.8 0.386
6/30(20.0) 15/44(34.1) 0.405
7/31(22.6) 13/38(34.2) 0.569
10.2 ± 13.8 10.9 ± 15.4 0.378
9.8 ± 13.8 11.8 ± 16.3 0.575
58.4 ± 32.7 54.9 ± 38.5 0.504
58.3 ± 32.5 55.2 ± 38.9 0.745
2/30(6.7) 4/44(9.1) 0.944
2/31(6.5) 4/38(10.5) 0.803
es among the three groups of the NSIP patients as classified at the time of
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66 months (range 12-108). Three cases were diagnosed as
having polymyositis (one case from i-NSIP-Ab + group, two
cases from i-NSIP-Ab- group), one as scleroderma (scl-70
positive and skin biopsy) and another one as microscopic
polyarteritis (from i-NSIP-AB-group, p-ANCA and MPO
positive, renal biopsy). Additionally, three cases in the i-
NSIP-Ab- group were later found to have positive autoanti-
bodies. Two cases were ANA positive (one at 1:640;
another at 1:1280), and another case was anti-Jo-1 positive.Table 2 Comparison of clinical features among three groups
SAD-NSIP
N (%)
Cough, initial presentation 14/23(60.9)
After follow up 17/28(60.7)
Dyspnea, initial presentation 13/23(56.5)
After follow up 17/28(60.7)
Fever, initial presentation 5/23(21.7)
After follow up 9/28(36.0)
Weight loss, initial presentation 1/23(4.3)
After follow up 3/28(10.7)
Arthralgia, initial presentation 5/23(21.7)
After follow up 7/28(25.0)
Raynaud’s phenomenon, initial presentation 3/23(13.0)
After follow up 3/28(10.7)
Dry eyes or dry mouth, initial presentation 3/23(13.0)
After follow up 3/28(10.7)
Oral ulcer, initial presentation 4/23(17.4)
After follow up 4/28(14.3)
Skin rash, initial presentation 8/23(34.8)
After follow up 8/28(28.6)
Proximal muscle weakness, initial presentation 3/23(13.0)
After follow up 3/28(10.7)
Morning stiffness, initial presentation 2/23(10.7)
After follow up 2/28(7.1)
Gastroesophageal reflux, initial presentation 2/23(8.7)
After follow up 2/28(7.1)
Photosensitivity, initial presentation 0
After follow up 0
Crackles, initial presentation 17/23(73.9)
After follow up 18/28(64.3)
Clubbing, initial presentation 2/23(8.7)
After follow up 2/28(7.1)
*Skin rash was strongly associated with the ASD-NSIP and i-NSIP-Ab + groups relativ
after re-classification.
**Morning stiffness and Gastroesophageal reflux were associated with ASD-NSIP at
re-classification at the time of follow-up.
ASD = systemic autoimmune disease.At the end of December 2012, the underlying types
of systemic autoimmune disease were rheumatoid arthritis
(n = 3), scleroderma (n =4), Sjogren’s syndrome (n =4),
polymyositis (n = 12), SLE (n = 1), MPA (n = 3) and ul-
cerative colitis (n = 1). We re-classified the NSIP pa-
tients according the follow-up results. The post-follow-up
distribution of the subjects was: 28/97 patients (28.9%)
in the SAD-NSIP group, 31/97 (32.0%) in the i-NSIP-
Ab + group and 38/97 (39.1%) in the i-NSIP-Ab-
group.i-NSIP-Ab+ i-NSIP-Ab- P































e to the i-NSIP-Ab- group at the time of surgical lung biopsy or
the time of surgical lung biopsy. No differences among the three groups after
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i-NSIP-Ab + and i-NSIP-Ab- groups
The demographic characteristics are shown in Table 1.
There were no differences among the three groups of the
NSIP patients as classified at the time of surgical lung
biopsy or after re-classification at the time of follow-up
(a median of 45 months).
The clinical characteristics of study subjects are
shown in Table 2. Skin rash was strongly associated
with the SAD-NSIP and i-NSIP-Ab + groups relative
to the i-NSIP-Ab- group as classified at the time of
surgical lung biopsy or after re-classification at the
time of follow-up.
The laboratory data are shown in Table 3. There
were no differences among the three groups either at
the time of the surgical lung biopsy or after the post-
follow-up reclassification. Pulmonary function, BAL
lymphocytes analysis and ABG were similar among the
three groups at the time of surgical lung biopsy or
after the post-follow-up reclassification.Table 3 Comparison of LAB findings among three groups
SAD-NSIP group
ABG
PaO2 (mmHg), initial presentation 74.1 ± 8.9
After follow up 73.0 ± 10.7
PaCO2(mmHg), initial presentation 36.8 ± 4.9
After follow up 37.1 ± 4.9
PFT
FVC (%), initial presentation 70.1 ± 16.3
After follow up 68.9 ± 14.9
TLC (%), initial presentation 75.1 ± 12.4
After follow up 73.4 ± 11.7
DLCO (%), initial presentation 55.1 ± 10.9
After follow up 51.4 ± 11.0
BALF
M (%), initial presentation 42.9 ± 21.7
After follow up 46.9 ± 24.7
L (%), initial presentation 39.2 ± 20.9
After follow up 37.1 ± 22.8
N (%), initial presentation 10.1 ± 18.2
After follow up 11.9 ± 19.6
E (%), initial presentation 5.0 ± 8.8
After follow up 5.3 ± 8.2
CD4/CD8, initial presentation 1.5 ± 1.9
After follow up 1.2 ± 1.8
ABG, PFTs and BAL lymphocytes analysis were similar among the three groups. The
surgical lung biopsy or after the post-follow-up reclassification.
ABG = arterial blood gas analysis; BAL = Bronchial alveolus lavage; PFT = pulmonaryRadiologic and pathologic findings in CTD-NSIP, i-NSIP-Ab +
and i-NSIP-Ab- groups
The characteristic features of the HRCT for the three
groups are shown in Table 4. No statistically significant
differences were observed among the three groups of pa-
tients as classified at the time of surgical lung biopsy or
after the post-follow-up reclassification.
The histological analysis is shown in Table 4. Addition-
ally, no statistically significant differences were observed
among the three subgroups of patients as classified at the
time of surgical lung biopsy or after the post-follow-up
reclassification.
Treatment and survival
The treatment and follow-up results are summarized in
Table 5.
Based on the classification at the time of surgical lung
biopsy, there were no significant differences among the
three groups, p = 0.511 (Kaplan-Meier survival curves are
shown in Figure 1). The diagnosis of systemic autoimmunei-NSIP-Ab + group i-NSIP-Ab-group p
74.2 ± 10.8 74.2 ± 10.8 0.648
73.2 ± 11.8 73.9 ± 10.6 0.934
35.3 ± 4.2 35.7 ± 4.5 0.478
35.4 ± 4.2 35.2 ± 4.1 0.206
72.3 ± 13.5 74.5 ± 12.3 0.789
74.1 ± 14.7 75.7 ± 14.4 0.664
74.1 ± 13.2 73.4 ± 12.1 0.912
74.4 ± 14.9 76.0 ± 17.6 0.847
53.4 ± 16.2 52.1 ± 15.2 0.198
54.2 ± 18.0 56.8 ± 16.6 0.173
43.8 ± 22.6 45.6 ± 23.7 0.397
44.0 ± 21.7 43.6 ± 24.3 0.425
38.9 ± 22.4 41.3 ± 23.5 0.876
38.4 ± 20.7 44.8 ± 25.0 0.776
13.6 ± 14.2 12.1 ± 11.9 0.671
13.2 ± 15.7 10.5 ± 13.1 0.807
5.2 ± 6.0 4.1 ± 5.0 0.801
4.8 ± 5.7 3.9 ± 4.6 0.752
1.3 ± 1.3 1.2 ± 0.9 0.813
1.2 ± 1.1 1.4 ± 1.5 0.947
re were no differences among the three groups either at the time of the
function tests.
Table 4 Comparison of chest CT and pathological findings among three groups
SAD-NSIP i-NSIP-Ab+ i-NSIP-Ab- P
n (%) n (%) n (%)
Baseline Chest CT Findings
Ground glass opacity, initial presentation 17/23(73.9) 20/30(66.7) 25/44(56.8) 0.358
After follow up 19/28(67.9) 21/31(67.7) 23/38(60.5) 0.765
Patchy opacity, initial presentation 9/23(39.1) 10/30(33.3) 12/44(27.2) 0.602
After follow up 10/28(35.7) 11/31(35.5) 10/38(26.3) 0.633
Reticular opacity, initial presentation 18/23(78.2) 19/30(63.3) 27/44(61.4) 0.358
After follow up 22/28(78.6) 20/31(64.5) 22/38(57.9) 0.211
Traction bronchiectasis, initial presentation 9/23(39.1) 6/30(20.0) 8/44(18.2) 0.167
After follow up 10/28(35.7) 6/31(19.4) 7/38(18.4) 0.208
Pathological pattern
Cellular pattern, initial presentation 12/23(52.2) 15/30(50.0) 22/44(50.0) 0.984
After follow up 15/28(53.6) 14/31(45.2) 20/38(52.6) 0.768
Mixed pattern, initial presentation 8/23(34.8) 13/30(43.3) 17/44(38.6) 0.815
After follow up 10/28(35.7) 14/31(45.2) 14/38(36.8) 0.707
Fibrotic pattern, initial presentation 3/23(13.0) 2/30(6.7) 5/44(11.4) 0.716
After follow up 3/28(10.7) 4/31(12.9) 3/38(7.9) 0.791
The characteristic features of HRCT and histo-pathological pattern of the three groups are seen in this table. No statistically significant differences were observed
among the three groups as classified at the time of surgical lung biopsy or after the post-follow-up reclassification.
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0.368, 95% CI, 0.680-3.067; p = 0.339). However, based
on the classification after the follow-up period, a mar-
ginally significant statistical difference could be observed
between the ASD-NSIP and NSIP-Ab- groups (Figure 2,
p = 0.059). Systemic autoimmune disease was an inde-
pendent risk factor for the survival of patients with NSIP
after follow-up (HR, 0.471; 95% CI, 0.246-0.901; p = 0.023).
Pathological pattern was associated with the survival
time, p = 0.010 (Kaplan-Meier survival curves are shown
in Figure 3). There is a significant difference (p = 0.01)
among three groups (Log Rank=13.391). Fibrotic patternTable 5 Comparison of treatment and outcomes among three
SAD-NSIP g
Initial therapy
Prednisone, N (%) 9/23(39.1)
Prednisone + immunosuppressive agent, N (%) 14/23(60.9)
Relapse, N (%) 6/23(26.1)
Emerging autoantibody, N (%) 0
classifiable SAD, N (%) 0
PAH, N (%) 1/23(4.3)
Lung infection, N (%) 1/23(4.3)
Death, N (%) 8/23(34.8)
Underlying disease, N (%) 4/23(17.4)
Lung infection, N (%) 3/23(13.0)
Other, N (%) 1/23(4.3)was an independent risk factor for the survival of patients
with NSIP (HR, 0.316; 95% CI, 0.115-0.870; p = 0.026).
Smoking (HR, 0.964; 95% CI, 0.348-2.679; p = 0.943),
TLC (HR, 1.013; 95% CI, 0.991-1.036; p = 0.260), FVC
(HR, 1.032; 95% CI, 0.997-1.067; p = 0.764) and DLCO
(HR, 0.978; 95% CI, 0.945-1.012; p = 0.206) were not the
risk factor for survival.
Our study revealed a total of 5/74 (6.8%) cases were
diagnosed as having systemic autoimmune disease after
follow-up. Romagnoli’s study showed that 3 of 27 (11%)
i-NSIP patients were diagnosed as having CTD after a
follow-up of 59.7 months [13]. Park reported that 8/87groups













Figure 1 Kaplan-Meier survival curve for NSIP patients divided by clinical status at intital: SAD-NSIP, i- NSIP-AB+ and i-NSIP-Ab- patients at
the time of surgical lung biopsy. There is no significant difference (p = 0.511) among three groups (Log Rank = 1.342).
Figure 2 Kaplan-Meier survival curve for NSIP patients re-divided by clinical status after follow up 54 ± 34 months. ASD-NSIP vs i-NSIP-Ab- =0.059;
ASD-NSIP vs i-NSIP-Ab + =0.232; i-NSIP-Ab + vs i-NSIP-Ab- =0.456.
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p=0.01
Figure 3 Kaplan-Meier survival curve for NSIP patients divided by pathological pattern: cellular pattern vs mixed pattern =0.001;
cellular pattern vs fibrotic pattern =0.000; Mixed pattern vs fibrotic pattern =0.451.
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median follow-up of 53 months [14]. The prevalence in
these previous studies was higher than in our study. One
reason for the difference could be that the median follow-
up time in our study was 45 months, but the typical
systemic autoimmune disease symptoms, signs and serum
biomarkers were generally first observed at times between
48 and 66 months of follow-up. It is therefore possible that
some of the i-NSIP patients might have developed typical
systemic autoimmune disease after our follow-up period.
We reviewed the published papers that compared sur-
vival between CTD-ILD and IIP and found that all of the
studies classified the patients according to the patient’s pre-
sentations at the time of the first visit. The results indicated
that the clinical and radiologic features of CTD-NSIP were
similar to idiopathic NSIP [22,23], and CTD did not affect
survival in NSIP patients [24,26]. In our study, we followed
the methods of the previous studies and divided the pa-
tients according the clinical manifestation at the time of
surgical lung biopsy. The results were consistent with the
previous studies in showing no differences in survival time
among those three NSIP classifications [18,41,42]. i-NSIP-
Ab +was also not associated with a survival benefit accord-
ing to several studies [18,23,43]. Then, we re-classified
the NSIP patents according the follow-up results and
compared the patients’ clinical manifestations, radiographic
findings and pathological features. There were still no dif-
ferences among three groups after follow-up. The patientswho were defined as having systemic autoimmune disease
associated NSIP could not be distinguished from those who
were defined as i-NSIP with or without antibodies based on
pulmonary manifestations or respiratory physiology even
after follow-up. This result indicates that recognition of
systemic autoimmune disease is particularly challenging
in NSIP [25,26,44,45].
Using Cox multivariate analysis, we found that systemic
autoimmune disease was a risk factor for survival. Further-
more, we found that the survival times for the SAD-NSIP
patients were shorter than for those classified as i-NSIP
because some i-NSIP patients with poor prognoses were
eventually diagnosed as having systemic autoimmune dis-
ease and were re-assigned to the SAD-NSIP group. Lee’s
study showed that the patients with NSIP and various
systemic conditions had worse prognoses. However, no
statistically significant relationship was found between the
systemic conditions and poor prognosis in that study [42].
Felício [24] detected significantly greater collagen and elas-
tic fiber production in the lungs of patients with CTD-
NSIP compared with those with idiopathic NSIP [24]. The
increased elastin content may have been caused by major
repair and remodeling processes following septal inflam-
mation and consequent fiber fragmentation in CTD-NSIP.
These processes might be responsible for the worse prog-
nosis. However, the specific mechanism is currently uncer-
tain. More prospective studies with larger numbers of
subjects are required.
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because this was a retrospective study, the subjects were
restricted to the patients who had undergone a surgical
lung biopsy. In addition, the follow-up period might not
have been long enough to clearly show differences in the
prognosis between SAD-NSIP and i-NSIP. Although the
number of subjects in our study was relatively large, it
might not have been enough to clearly show the differ-
ences between SAD-NSIP and i-NSIP. Further studies of
larger numbers of subjects, perhaps through multicenter
cooperation, will be required to overcome this limitation.
Nevertheless, this is the first time that the NSIP patients
were re-classified after the follow-up period. We believe
that the data presented here remain valid despite these
shortcomings.
Conclusion
Based on the results of our study, we concluded that some
idiopathic NSIP cases may represent the first manifest-
ation of an underlying systemic autoimmune disease.
Long-term follow-up of patients with idiopathic NSIP is
recommended.
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